Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
June 16, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
June 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
May 04, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
May 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
April 06, 2022
Via
Investor Brand Network
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
April 06, 2022
Via
Investor Brand Network
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
April 29, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
April 27, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 26, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
April 12, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
February 08, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
February 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
February 01, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
January 24, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
January 10, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
December 21, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
November 30, 2021
From
Deciphera Pharmaceuticals
Via
Business Wire
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
November 22, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
November 05, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
November 02, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
October 26, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
October 12, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
September 17, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
September 17, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021
September 10, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
September 02, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
August 03, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
July 27, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.